The present invention provides a compound of Formula (I) as defined herein. The present invention also provides a nanoparticle comprising a plurality of the conjugates of the present invention, and methods of using the nanoparticles for drug delivery, treating a disease, and methods of imaging.

A biocompatible curable composition and a method of detecting a border of a tumor, a tissue of interest, or both including injecting the biocompatible curable composition and contacting the border of a tumor or a tissue, the biocompatible curable composition crosslinks to form a three-dimensional cured nanocomposite, and imaging the three-dimensional (3D) cured nanocomposite, and imaging the 3D cured nanocomposite by at least one of MRI, CT, ultrasound, and X-ray, to detect the border of the tumor or the tissue of interest or track tumor motion during radiotherapy treatment. The biocompatible curable composition comprising an organic polymer having a hydrolysable functional group, a metallic nanoparticle, and a polar or a non-polar solvent. A brachytherapy strand consisting of a biocompatible curable composition and a radio-isotope seed. The biocompatible curable composition is shaped into an elongated cylinder and forms a 3D cured nanocomposite with a radio-isotope seed embedded.

A self-assembled nanostructure including an amphiphilic chitosan and a contrast agent compound is provided. The contrast agent compound is grafted to the amphiphilic chitosan. The chemical bonding between the amphiphilic chitosan and the contrast agent compound has a synergistic effect to further improve the contrasting ability of the contrast agent compound.

Various oil-in-water (O/W) nanoemulsions containing an oil phase or oil core, preferably selected from vitamin E or oleic acid, stabilized by a sphingolipid of the sphingomyelin type, and optionally other lipids such as phospholipids, cholesterol, octadecylamine, DOTAP (N-[1-(2,3-Dioleoyloxy) propyl]-N, N, N-trimethylammonium methyl-sulfate), and PEGylated derivatives (derivatives with polyethylene glycol), for use as a nanotech vehicle, for example for the management of cancer and metastatic disease. Said nanoemulsions can be functionalized with ligands capable of interacting or binding to receptors expressed on the cell membrane of tumor cells, and in particular capable of interacting or binding to receptors expressed on the membrane of primary and/or disseminated or metastatic tumor cells. Also, antitumor drugs or therapeutic biomolecules can be encapsulated in said nanoemulsions and, finally, contrast agents can be incorporated for their use in the in vivo diagnosis in said nanoemulsions.

A method for colon screening and collecting data by using Magnetic Particle Imaging wherein an imaging magnetic field is generated with a spatial distribution of the magnetic field strength such that the area of examination in the colon consists of a first sub-area with lower magnetic field strength, where the magnetization of a magnetic particle which was pre-delivered to the colon is not saturated, and a second sub-area with a higher magnetic field strength, where the magnetization of said magnetic particle is saturated. The spatial location of both sub-areas in the area of examination is modified so that the magnetization of said particles changes locally. Signals are acquired and are evaluated to obtain information about the spatial distribution of the signals in the area of examination. The method may be carried out during an entire peristaltic cycle in a colon portion or segment.

The present invention provides a safe polymer nanoparticle composite with few side effects, and an MRI contrast agent incorporating said polymer nanoparticle composite. The polymer nanoparticle composite is capable of specifically accumulating on a tumor tissue to selectively extract the tissue, exhibiting high contrast even when used in small amounts, and enabling imaging over prolonged periods of time. This polymer nanoparticle composite is characterized by containing a block copolymer that includes a non-charged hydrophilic polymer chain segment and an anionic polymer chain segment, and MnCaP.

Provided is a fluoride nanophosphor using, as cores, luminescent nanoparticles expressed by Chemical Formula 1.
LiEr.sub.1-x-yL.sub.yF.sub.4:Tm.sup.3+.sub.x  [Chemical Formula 1] (In Chemical Formula 1, x is a real number satisfying 0≤x≤0.3, y is a real number satisfying 0≤y≤0.8 and is selected within a range satisfying 0≤x+y≤0.9, and L is any one selected from the group consisting of yttrium (Y), lanthanum (La), cerium (Ce), praseodymium (Pr), neodymium (Nd), promethium (Pm), samarium (Sm), europium (Eu), gadolinium (Gd), terbium (Tb), dysprosium (Dy), holmium (Ho), ytterbium (Yb), lutetium (Lu), and a combination thereof.)

A system and method of imaging tissue includes administering a contrast agent having charged gold nanoparticles in suspension into a vessel of the subject, such that the nanoparticles are carried into the tissue; and performing microwave imaging of the tissue after administering the contrast agent. In embodiments, the nanoparticles have a tissue-selective protein tag. In embodiments, images are taken prior to administering the contrast agent, and further images may be taken during an agent—washout period after imaging with contrast agent. The contrast agent is injectable, with the nanoparticles suspended as a colloid in a biocompatible, isotonic, carrier. In particular embodiments, the nanoparticles have median diameter of less than fifty nanometers, or less than five nanometers, and may have a tissue-selective protein tag. A microwave imaging system has injection apparatus with the gold-nanoparticle agent, and is configured to take, and difference, pre and post contrast images as well as washout images.

3D cine MR angiography systems and methods are disclosed for use during the steady state intravascular distribution phase of ferumoxytol. The 3D cine MRA technique enables improved delineation of cardiac anatomy in pediatric patients undergoing cardiovascular MRI.

A method of imaging an organism includes introducing a composite nanoparticle into a circulating fluid of an organism to form a circulating fluid mixture in the organism is provided. The composite nanoparticle comprises a core comprising at least one of a contrast agent and a magnetic material, and at least one layer of biocompatible material surrounding the core. The method further includes receiving an image of at least a portion of the organism where the circulating fluid has circulated, removing at least a portion of the circulating fluid mixture from the organism at a first rate, applying a magnetic field to the removed portion of the circulating fluid mixture to selectively remove the composite nanoparticle from the circulating fluid mixture and to produce a filtered fluid mixture, and returning the filtered fluid mixture to the circulating fluid of the organism at a second rate.